PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Institut für Virologie und Immunbiologie, Julius-Maximilians-Universität Würzburg, Würzburg, Germany.\', \'Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, Member of Fraunhofer International Consortium for Anti-Infective Research (iCAIR), Member of the German Center for Lung Research (DZL), Biomedical Research in Endstage and Obstructive Lung Disease (BREATH), Hannover, Germany.\', \'Lehrsstuhl Für Tissue Engineering und Regenerative Medizin, Würzburg, Germany.\', \'Institute of Organic Chemistry, Julius-Maximilians-Universität Würzburg, Würzburg, Germany.\', \'Institut für Virologie und Immunbiologie, Julius-Maximilians-Universität Würzburg, Würzburg, Germany. Jochen.Bodem@vim.uni-wuerzburg.de.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1038/s41598-021-85049-0
?:hasPublicationType
?:journal
  • Scientific reports
is ?:pmid of
?:pmid
?:pmid
  • 33723270
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.533
?:rankingScore_hIndex
  • 122
?:title
  • The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all